| Name | Title | Contact Details |
|---|
Cultivation. Commercialization. Logistics. Yes, we`re here to make your life and work happier, and it starts with remarkable cannabis. It continues with business-ready services which help simplify the regulated world. From our proud home in Huntingdon, our family of marketers, growers and industry leaders at ROSE LifeScience are making cannabis thrive in Québec — for our customers, partners, communities and (especially) for you. Happiness is indeed our business. More importantly, it`s the reason why we do business.
Neurovia, Inc. operates in the pharmaceutical industry. The company was founded in 2013 and is based in San Francisco CA.
PMV is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutations. p53 mutations are found in approximately half of all cancers. The field of p53 biology was established by our co-founder Dr. Arnold Levine when he discovered the p53 protein in 1979. Bringing together leaders in the field to utilize over three decades of p53 biology, PMV Pharma combines unique biological understanding with pharmaceutical development focus. PMV Pharma is headquartered in Cranbury, New Jersey.
We are a pharma research and drug discovery company.
Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. The company is developing three small molecule products: its lead development program, IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect, is currently being developed as a treatment option for multiple sclerosis, ulcerative colitis, Crohn`s disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγt, is targeted for development in psoriasis and Guillain-Barré syndrome. IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction.